The serum CRP remaining stable in the 7–11 mg/L range in all four trials suggests that increasing serum ferritin at later times in both NDD‐CKD trials and the incident DD‐CKD trial was likely due to iron administrations rather than changes in inflammation. Here, CRP is linked to chronic kidney disease.